November 2016 Newsletter

November 16, 2016:

Trump Presidency Expected to Leave Imprint on Ophthalmology Business

The new administration is likely to target the Affordable Care Act and America’s unfavorable corporate tax rate.

November 16, 2016:

Manufacturing Issues Delay Four NDAs for Ophthalmic Products

FDA inspection process holds up expected approvals for Aerie, Bausch + Lomb, Nicox, and Ocular Therapeutix.

November 16, 2016:

Sun Pharma Acquires Seciera Dry Eye Technology from Auven for $40 Million

The cyclosporine ophthalmic solution is being studied in a Phase III confirmatory trial in the US.

November 16, 2016:

Shire Reports Strong Launch of Xiidra

The product captured 16 percent of the dry eye market with $14 million in sales, Shire said.

November 16, 2016:

Allergan Launches Restasis Multidose

The bottle uses less plastic than a package of single-use vials and is available for the same price.

November 16, 2016:

Allergan’s Restasis Net Sales Increase 13.3 Percent in Q3-2016

The company told analysts that the dry eye market expanded significantly during the quarter.

November 16, 2016:

ReVision Optics Raises $32 Million to Expand Use of Raindrop; J&J Leads Round

The company said 100 surgeons have scheduled patients for implantation of the inlay.

November 16, 2016:

MillennialEYE Live Attendees Applaud New Product Approvals

Key takeaway message of 2016 meeting was companies and surgeons achieve more together.

November 16, 2016:

Novartis Chairman Weighs Possible Sale of Alcon after Q3-2016 Revenues Dip 2 Percent

Joerg Reinhardt said all options are open after the US-based eye care division failed to develop as expected.

November 16, 2016:

Bausch + Lomb Sees Growth While Rest of Valeant Portfolio Experiences Declines

Eye care segment contributed 47 percent of the company’s total revenues.

November 16, 2016:

Alimera Sciences Posts Q3-2016 Net Revenues of $8.3 Million, a 20 Percent Increase

The company said the increase was driven by growth in sales volume of Alimera’s lead product, Iluvien.

November 16, 2016:

Abbott’s Medical Optics Division Sees 4.4 Percent Sales Increase in Advance of Johnson & Johnson Sale

The company launched its TECNIS Symfony lens during Q3-2016.

November 16, 2016:

Ophthotech’s Development Expenses Increase to $50.9 Million, as Fovista Advances

The company expects to announce topline data from Phase III trials of Fovista in combination with Lucentis for wet AMD in Q4-2016.

November 16, 2016:

Imprimis Revenues Up 81 Percent in Q3-2016; Cataract Eye Drops Gain Market Share of 10 Percent

Company said its products have been used in an estimated 375 thousand ocular surgeries.

November 16, 2016:

Q3-2016 Earnings Briefs

November 16, 2016:

EU-5 Ophthalmic Market to Grow More than 5 Percent through 2021

Revenues are expected to total $7.6 billion by 2021.

November 16, 2016:

FDA Rethinks Off-Label Marketing of Drugs, Devices

Recent court cases have backed manufacturers’ rights to share truthful information.

November 16, 2016:

FDA Drug Division Struggles to Fill 700 Openings

Job candidates find better pay and quicker hiring process at manufacturers.

November 16, 2016:

Q3-2016 Survey: Glaucoma Specialists Rate ‘Patient Compliance’ as Top Benefit of Sustained-Release Drugs

Several companies are currently pursuing this technology, recognizing the need to address the continued challenges with daily eye drop regimens.

November 16, 2016:

AMA Launches Website for Regular People to Explain How Drug Prices Affect Them

TruthinRx.org also will lobby Congress to make drug pricing more transparent.

November 16, 2016:

November 2016 News Briefs

Social media